Coagulation considerations for infants and children undergoing cardiopulmonary bypass

Paediatric Anaesthesia

Volumn 21, Issue 1, 2011, Pages 31-42

  Eaton, Michael P ^a   Iannoli, Ellen M ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

antifibrinolytic; cardiac surgery; coagulation; congenital heart disease; heparin; protamine

Indexed keywords

4 (4 AMIDINOPHENOXY)BUTYRYLASPARTYLVALINE; ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; ARGATROBAN; BLOOD CLOTTING FACTOR; CANGRELOR; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; HEPARIN; HIRUDIN; HIRULOG; INOTROPIC AGENT; NITRIC OXIDE; PROSTACYCLIN; PROTAMINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; TIROFIBAN; TRANEXAMIC ACID;

ANESTHESIA; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; BODY WEIGHT; CARDIOPULMONARY BYPASS; CHILD; CONGENITAL HEART DISEASE; CYANOTIC HEART DISEASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PROTEIN BINDING; HEART SURGERY; HEMODILUTION; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INFANT; KIDNEY FAILURE; LOADING DRUG DOSE; PATHOPHYSIOLOGY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK; SINGLE DRUG DOSE; SURGICAL EQUIPMENT; SURGICAL TECHNIQUE; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

ADOLESCENT; AGING; ANESTHESIA; ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION; CARDIOPULMONARY BYPASS; CHILD; CHILD, PRESCHOOL; FACTOR VIIA; HEART DEFECTS, CONGENITAL; HEMOSTASIS; HUMANS; INFANT; INFUSION PUMPS; INTRAOPERATIVE COMPLICATIONS; PATIENT CARE PLANNING; PERIOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE;

EID: 78650356248     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/j.1460-9592.2010.03467.x     Document Type: Review

References (140)

1. Mammen EF, Koets MH, Washington BC, et al. Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost 1985; 11: 281-292.
2. Kirklin JK, Blackstone EH, Kirklin JW,. Cardiopulmonary bypass: studies on its damaging effects. Blood Purif 1987; 5: 168-178.
3. Weiland AP, Walker WE,. Physiologic principles and clinical sequelae of cardiopulmonary bypass. Heart Lung 1986; 15: 34-39.
4. Williams GD, Bratton SL, Riley EC, et al. Association between age and blood loss in children undergoing open heart operations. Ann Thorac Surg 1998; 66: 870-875. Discussion 875-876.
5. Bick RL,. Alterations of hemostasis associated with cardiopulmonary bypass: pathophysiology, prevention, diagnosis, and management. Semin Thromb Hemost 1976; 3: 59-82.
6. Kern FH, Morana NJ, Sears JJ, et al. Coagulation defects in neonates during cardiopulmonary bypass. Ann Thorac Surg 1992; 54: 541-546.
7. Campbell DJ, Dixon B, Kladis A, et al. Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1059-R1070.
8. De Somer F, Van Belleghem Y, Caes F, et al. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2002; 123: 951-958.
9. Edmunds LH Jr, Colman RW,. Thrombin during cardiopulmonary bypass. Ann Thorac Surg 2006; 82: 2315-2322.
10. Addonizio VP Jr, Smith JB, Strauss JF III, et al. Thromboxane synthesis and platelet secretion during cardiopulmonary bypass with bubble oxygenator. J Thorac Cardiovasc Surg 1980; 79: 91-96.
11. Slaughter TF, Sreeram G, Sharma AD, et al. Reversible shear-mediated platelet dysfunction during cardiac surgery as assessed by the PFA-100 platelet function analyzer. Blood Coagul Fibrinolysis 2001; 12: 85-93.
12. Reilly TM, Forsythe MS, Racanelli AL, et al. Recombinant plasminogen activator inhibitor-1 protects platelets against the inhibitory effects of plasmin. Thromb Res 1993; 71: 61-68.
13. Esmon CT,. The interactions between inflammation and coagulation. Br J Haematol 2005; 131: 417-430.
14. Koster A, Chew D, Kuebler W, et al. High antithrombin III levels attenuate hemostatic activation and leukocyte activation during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2003; 126: 906-907.
15. Cappabianca G, Rotunno C, De Luca Tupputi Schinosa L, et al. Protective Effects of Steroids in Cardiac Surgery: A Meta-Analysis of Randomized Double-Blind Trials. J Cardiothorac Vasc Anesth 2010; (in press).
16. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70: 165-172.
17. Kuhle S, Male C, Mitchell L,. Developmental hemostasis: pro- and anticoagulant systems during childhood. Semin Thromb Hemost 2003; 29: 329-338.
18. Albisetti M,. The fibrinolytic system in children. Semin Thromb Hemost 2003; 29: 339-348.
19. Ries M, Easton RL, Longstaff C, et al. Differences between neonates and adults in tissue-type-plasminogen activator (t-PA)-catalyzed plasminogen activation with various effectors and in carbohydrate sequences of fibrinogen chains. Thromb Res 2001; 103: 173-184. (Pubitemid 32728102)
20. Ries M, Easton RL, Longstaff C, et al. Differences between neonates and adults in carbohydrate sequences and reaction kinetics of plasmin and alpha(2)-antiplasmin. Thromb Res 2002; 105: 247-256.
21. Zenker M, Ries M,. Differences between neonates and adults in plasmin inhibitory and antifibrinolytic action of aprotinin. Thromb Res 2002; 107: 17-21.
22. Bahnson H, Ziegler R,. A Consideration of the causes of death following operation for congenital heart disease of the cyanotic type. Surg Gynecol Obstet 1950; 90: 60-76.
23. Goldschmidt B, Sarkadi B, Gardos G, et al. Platelet production and survival in cyanotic congenital heart disease. Scand J Haematol 1974; 13: 110-115.
24. Gill JC, Wilson AD, Endres-Brooks J, et al. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood 1986; 67: 758-761.
25. Beguin Y,. Erythropoietin and platelet production. Haematologica 1999; 84: 541-547.
26. Gross S, Keefer V, Liebman J,. The platelets in cyanotic congenital heart disease. Pediatrics 1968; 42: 651-658.
27. Henriksson P, Varendh G, Lundstrom NR,. Haemostatic defects in cyanotic congenital heart disease. Br Heart J 1979; 41: 23-27.
28. Waldman JD, Czapek EE, Paul MH, et al. Shortened platelet survival in cyanotic heart disease. J Pediatr 1975; 87: 77-79.
29. Mauer HM, McCue CM, Caul J, et al. Impairment in platelet aggregation in congenital heart disease. Blood 1972; 40: 207-216.
30. Bhargava M, Sanyal SK, Thapar MK, et al. Impairment of platelet adhesiveness and platelet factor 3 activity in cyanotic congenital heart disease. Acta Haematol 1976; 55: 216-223.
31. Brodsky I, Gill DN, Lusch CJ,. Fibrinolysis in congenital heart disease. Preoperative treatment with epsilon-aminocaproic acid. Am J Clin Pathol 1969; 51: 51-57.
32. Dennis LH, Stewart JL, Conrad ME,. Heparin treatment of haemorrhagic diathesis in cyanotic congenital heart-disease. Lancet 1967; 1: 1088-1089.
33. Cholette JM, Rubenstein JS, Alfieris GM, et al. Elevated risk of thrombosis in neonates undergoing initial palliative cardiac surgery. Ann Thorac Surg 2007; 84: 1320-1325.
34. Odegard KC, Zurakowski D, DiNardo JA, et al. Prospective longitudinal study of coagulation profiles in children with hypoplastic left heart syndrome from stage I through Fontan completion. J Thorac Cardiovasc Surg 2009; 137: 934-941.
35. Khuri SF, Wolfe JA, Josa M, et al. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg 1992; 104: 94-107.
36. Paparella D, Brister SJ, Buchanan MR,. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 2004; 30: 1873-1881.
37. Mossinger H, Dietrich W, Braun SL, et al. High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery. Ann Thorac Surg 2003; 75: 430-437.
38. Groom RC, Froebe S, Martin J, et al. Update on pediatric perfusion practice in North America: 2005 survey. J Extra Corpor Technol 2005; 37: 343-350.
39. Karamlou T, Schultz JM, Silliman C, et al. Using a miniaturized circuit and an asanguineous prime to reduce neutrophil-mediated organ dysfunction following infant cardiopulmonary bypass. Ann Thorac Surg 2005; 80: 6-13. Discussion 13-14.
40. Spiess BD,. Transfusion of blood products affects outcome in cardiac surgery. Semin Cardiothorac Vasc Anesth 2004; 8: 267-281.
41. Zannini L, Borini I,. State of the art of cardiac surgery in patients with congenital heart disease. J Cardiovasc Med (Hagerstown) 2007; 8: 3-6.
42. Williams GD, Bratton SL, Ramamoorthy C,. Factors associated with blood loss and blood product transfusions: a multivariate analysis in children after open-heart surgery. Anesth Analg 1999; 89: 57-64.
43. Despotis GJ, Joist JH, Hogue CW, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. J Thorac Cardiovasc Surg 1994; 110: 46-54.
44. Hirsh J, Anand SS, Halperin JL, et al. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol 2001; 21: 1094-1096.
45. Dietrich W, Braun S, Spannagl M, et al. Low preoperative antithrombin activity causes reduced response to heparin in adult but not in infant cardiac-surgical patients. Anesth Analg 2001; 92: 66-71.
46. Koster A, Fischer T, Gruendel M, et al. Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation. J Cardiothorac Vasc Anesth 2003; 17: 171-175.
47. D'Errico C, Shayevitz JR, Martindale SJ,. Age-related differences in heparin sensitivity and heparin-protamine interactions in cardiac surgery patients. J Cardiothorac Vasc Anesth 1996; 10: 451-457.
48. Guzzetta NA, Miller BE, Todd K, et al. Clinical measures of heparin's effect and thrombin inhibitor levels in pediatric patients with congenital heart disease. Anesth Analg 2006; 103: 1131-1138.
49. Guzzetta NA, Miller BE, Todd K, et al. An evaluation of the effects of a standard heparin dose on thrombin inhibition during cardiopulmonary bypass in neonates. Anesth Analg 2005; 100: 1276-1282.
50. Owings JT, Pollock ME, Gosselin RC, et al. Anticoagulation of children undergoing cardiopulmonary bypass is overestimated by current monitoring techniques. Arch Surg 2000; 135: 1042-1047.
51. Guzzetta NA, Monitz HG, Fernandez JD, et al. Correlations Between Activated Clotting Time Values and Heparin Concentration Measurements in Young Infants Undergoing Cardiopulmonary Bypass. Anesth Analg 2010; 111: 173-179.
52. Guzzetta NA, Bajaj T, Fazlollah T, et al. A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass. Anesth Analg 2008; 106: 419-425.
53. Jaques LB,. The nitrogen partition in blood clotting. Biochem J 1938; 32: 1181-1184.
54. Kambam J, Meszaros R, Merrill W, et al. Prophylactic administration of histamine1 and histamine2 receptor blockers in the prevention of protamine-related haemodynamic effects. Can J Anaesth 1990; 37: 420-422.
55. Nybo M, Madsen JS,. Serious anaphylactic reactions due to protamine sulfate: a systematic literature review. Basic Clin Pharmacol Toxicol 2008; 103: 192-196.
56. Lowenstein E, Johnston WE, Lappas DG, et al. Catastrophic pulmonary vasoconstriction associated with protamine reversal of heparin. Anesthesiology 1983; 59: 470-473.
57. Seifert HA, Jobes DR, Ten Have T, et al. Adverse events after protamine administration following cardiopulmonary bypass in infants and children. Anesth Analg 2003; 97: 383-389.
58. Kimmel SE, Sekeres M, Berlin JA, et al. Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass. Anesth Analg 2002; 94: 1402-1408.
59. Griffin MJ, Rinder HM, Smith BR, et al. The effects of heparin, protamine, and heparin/protamine reversal on platelet function under conditions of arterial shear stress. Anesth Analg 2001; 93: 20-27.
60. Lindblad B, Wakefield TW, Whitehouse WM Jr, et al. The effect of protamine sulfate on platelet function. Scand J Thorac Cardiovasc Surg 1988; 22: 55-59.
61. Despotis GJ, Levine V, Filos KS, et al. Hemofiltration during cardiopulmonary bypass: the effect on anti-Xa and anti-IIa heparin activity. Anesth Analg 1997; 84: 479-483.
62. Trossaert M, Gaillard A, Commin PL, et al. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998; 101: 653-655.
63. Mullen MP, Wessel DL, Thomas KC, et al. The incidence and implications of anti-heparin-platelet factor 4 antibody formation in a pediatric cardiac surgical population. Anesth Analg 2008; 107: 371-378.
64. Boning A, Morschheuser T, Blase U, et al. Incidence of heparin-induced thrombocytopenia and therapeutic strategies in pediatric cardiac surgery. Ann Thorac Surg 2005; 79: 62-65.
65. Alsoufi B, Boshkov LK, Kirby A, et al. Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2004; 7: 155-171.
66. Koster A, Crystal GJ, Kuppe H, et al. Acute heparin-induced thrombocytopenia type II during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2000; 14: 300-303.
67. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340S-380S.
68. Riess F, Potzsch B, Behr I, et al. Recombinant hirudin as an anticoagulant during cardiac operations: experiments in a pig model. Eur J Cardiothorac Surg 1997; 11: 739-745. (Pubitemid 27180149)
69. Gates R, Yost P, Parker B,. The Use of Bivalirudin for Cardiopulmonary Bypass Anticoagulation in Pediatric Heparin-Induced Thrombocytopenia Patients. Artif Organs 2010; 34: 667-669.
70. Ciccolo ML, Bernstein J, Collazos JC, et al. Argatroban anticoagulation for cardiac surgery with cardiopulmonary bypass in an infant with double outlet right ventricle and a history of heparin-induced thrombocytopenia. Congenit Heart Dis 2008; 3: 299-302.
71. Riess FC, Poetzsch B, Madlener K, et al. Recombinant hirudin for cardiopulmonary bypass anticoagulation: a randomized, prospective, and heparin-controlled pilot study. Thorac Cardiovasc Surg 2007; 55: 233-238.
72. Follis F, Filippone G, Montalbano G, et al. Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative? Interact Cardiovasc Thorac Surg 2010; 10: 592-596.
73. Dyke CM, Smedira NG, Koster A, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006; 131: 533-539.
74. Kurup V, Transue S, Wu Y, et al. Cardiac surgery in a patient with heparin-induced thrombocytopenia - cautions with use of the direct thrombin inhibitor, argatroban. Conn Med 2006; 70: 245-250.
75. Gasparovic H, Nathan NS, Fitzgerald D, et al. Severe argatroban-induced coagulopathy in a patient with a history of heparin-induced thrombocytopenia. Ann Thorac Surg 2004; 78: e89-e91.
76. Welsby IJ, Jones WL, Arepally G, et al. Effect of combined anticoagulation using heparin and bivalirudin on the hemostatic and inflammatory responses to cardiopulmonary bypass in the rat. Anesthesiology 2007; 106: 295-301.
77. Paramo JA, Rifon J, Llorens R, et al. Intra- and postoperative fibrinolysis in patients undergoing cardiopulmonary bypass surgery. Haemostasis 1991; 21: 58-64.
78. Ray MJ, Marsh NA, Hawson GA,. Relationship of fibrinolysis and platelet function to bleeding after cardiopulmonary bypass. Blood Coagul Fibrinolysis 1994; 5: 679-685.
79. Jaggers JJ, Neal MC, Smith PK, et al. Infant cardiopulmonary bypass: a procoagulant state. Ann Thorac Surg 1999; 68: 513-520.
80. Miller BE, Guzzetta NA, Tosone SR, et al. Rapid evaluation of coagulopathies after cardiopulmonary bypass in children using modified thromboelastography. Anesth Analg 2000; 90: 1324-1330.
81. Eaton MP,. Antifibrinolytic therapy in surgery for congenital heart disease. Anesth Analg 2008; 106: 1087-1100.
82. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion- risk cardiac surgery. Transfusion 2006; 46: 327-338.
83. Mangano DT, Tudor IC, Dietzel C,. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353-365.
84. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358: 2319-2331.
85. Van der Staak FH, De Haan AF, Geven WB, et al. Surgical repair of congenital diaphragmatic hernia during extracorporeal membrane oxygenation: hemorrhagic complications and the effect of tranexamic acid. J Pediatr Surg 1997; 32: 594-599.
86. Bulutcu FS, Ozbek U, Polat B, et al. Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or a combination? Paediatr Anaesth 2005; 15: 41-46.
87. Chauhan S, Bisoi A, Kumar N, et al. Dose comparison of tranexamic acid in pediatric cardiac surgery. Asian Cardiovasc Thorac Ann 2004; 12: 121-124.
88. Chauhan S, Bisoi A, Modi R, et al. Tranexamic acid in paediatric cardiac surgery. Indian J Med Res 2003; 118: 86-89.
89. Chauhan S, Das SN, Bisoi A, et al. Comparison of epsilon aminocaproic acid and tranexamic acid in pediatric cardiac surgery. J Cardiothorac Vasc Anesth 2004; 18: 141-143.
90. Chauhan S, Kumar BA, Rao BH, et al. Efficacy of aprotinin, epsilon aminocaproic acid, or combination in cyanotic heart disease. Ann Thorac Surg 2000; 70: 1308-1312.
91. Rao BH, Saxena N, Chauhan S, et al. Epsilon aminocaproic acid in paediatric cardiac surgery to reduce postoperative blood loss. Indian J Med Res 2000; 111: 57-61.
92. Zonis Z, Seear M, Reichert C, et al. The effect of preoperative tranexamic acid on blood loss after cardiac operations in children. J Thorac Cardiovasc Surg 1996; 111: 982-987.
93. McClure PD, Izsak J,. The use of epsilon-aminocaproic acid to reduce bleeding during cardiac bypass in children with congenital heart disease. Anesthesiology 1974; 40: 604-608.
94. Williams GD, Bratton SL, Riley EC, et al. Efficacy of epsilon-aminocaproic acid in children undergoing cardiac surgery. J Cardiothorac Vasc Anesth 1999; 13: 304-308.
95. Ririe DG, James RL, O'Brien JJ, et al. The pharmacokinetics of epsilon-aminocaproic acid in children undergoing surgical repair of congenital heart defects. Anesth Analg 2002; 94: 44-49.
96. Eaton MPKK, Cable R, Haas CE, et al. The pharmacokinetics of epsilon-aminocaproic acid in neonates undergoing cardiac surgery. SCA 32nd annual meeting. New Orleans, 2010.
97. Yurka HG, Wissler RN, Zanghi CN, et al. The Effective Concentration of Epsilon-Aminocaproic Acid for Inhibition of Fibrinolysis in Neonatal Plasma in Vitro. Anesth Analg 2010; 111: 180-184.
98. Rinder CS,. Hematologic effects and coagulopathy. In:, Gravlee GP, Davis RF, Stammers AH, et al., eds. Cardiopulmonary Bypass, Principles and Practice. Philadelphia: Wolters Kluwer, 2008: 439-458.
99. Suzuki Y, Malekan R, Hanson CW III, et al. Platelet anesthesia with nitric oxide with or without eptifibatide during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg 1999; 117: 987-993.
100. Koster A, Chew DP, Kuebler W, et al. Effects of tirofiban on hemostatic activation and inflammatory response during cardiopulmonary bypass. Am J Cardiol 2003; 91: 346-347. (Pubitemid 36143879)
101. Tabata S, Yamaguchi S, Nagamine H, et al. Efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist on platelet preservation during and after cardiopulmonary bypass. Eur J Cardiothorac Surg 2004; 26: 289-293.
102. Kastrati A, Ndrepepa G,. Cangrelor-a champion lost in translation? N Engl J Med 2009; 361: 2382-2384.
103. Manno CS, Hedberg KW, Kim HC, et al. Comparison of the hemostatic effects of fresh whole blood, stored whole blood, and components after open heart surgery in children. Blood 1991; 77: 930-936.
104. Mou SS, Giroir BP, Molitor-Kirsch EA, et al. Fresh whole blood versus reconstituted blood for pump priming in heart surgery in infants. N Engl J Med 2004; 351: 1635-1644.
105. Gruenwald CE, McCrindle BW, Crawford-Lean L, et al. Reconstituted fresh whole blood improves clinical outcomes compared with stored component blood therapy for neonates undergoing cardiopulmonary bypass for cardiac surgery: a randomized controlled trial. J Thorac Cardiovasc Surg 2008; 136: 1442-1449.
106. Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008; 358: 1229-1239.
107. Ranucci M, Carlucci C, Isgro G, et al. Duration of red blood cell storage and outcomes in pediatric cardiac surgery: an association found for pump prime blood. Crit Care 2009; 13: R207.
108. Miyaji K, Kohira S, Miyamoto T, et al. Pediatric cardiac surgery without homologous blood transfusion, using a miniaturized bypass system in infants with lower body weight. J Thorac Cardiovasc Surg 2007; 134: 284-289.
109. Charette K, Hirata Y, Bograd A, et al. 180 ml and less: cardiopulmonary bypass techniques to minimize hemodilution for neonates and small infants. Perfusion 2007; 22: 327-331.
110. Hickey E, Karamlou T, You J, et al. Effects of circuit miniaturization in reducing inflammatory response to infant cardiopulmonary bypass by elimination of allogeneic blood products. Ann Thorac Surg 2006; 81: S2367-S2372.
111. Gomez D, Olshove VF, Weinstein S, et al. Use of a low-prime circuit for bloodless heart transplantation in xenotransplant of 5-7 kilogram primates. J Extra Corpor Technol 2000; 32: 138-141.
112. Gomez D, Preston TJ, Olshove VF, et al. Evaluation of air handling in a new generation neonatal oxygenator with integral arterial filter. Perfusion 2009; 24: 107-112.
113. Olsson C, Siegbahn A, Henze A, et al. Heparin-coated cardiopulmonary bypass circuits reduce circulating complement factors and interleukin-6 in paediatric heart surgery. Scand Cardiovasc J 2000; 34: 33-40.
114. Jensen E, Andreasson S, Bengtsson A, et al. Influence of two different perfusion systems on inflammatory response in pediatric heart surgery. Ann Thorac Surg 2003; 75: 919-925.
115. Suzuki Y, Daitoku K, Minakawa M, et al. Poly-2-methoxyethylacrylate- coated bypass circuits reduce activation of coagulation system and inflammatory response in congenital cardiac surgery. J Artif Organs 2008; 11: 111-116.
116. Deptula J, Glogowski K, Merrigan K, et al. Evaluation of biocompatible cardiopulmonary bypass circuit use during pediatric open heart surgery. J Extra Corpor Technol 2006; 38: 22-26.
117. Miyaji K, Hannan RL, Ojito J, et al. Heparin-coated cardiopulmonary bypass circuit: clinical effects in pediatric cardiac surgery. J Card Surg 2000; 15: 194-198.
118. Petaja J, Lundstrom U, Leijala M, et al. Bleeding and use of blood products after heart operations in infants. J Thorac Cardiovasc Surg 1995; 109: 524-529.
119. Miller BE, Mochizuki T, Levy JH, et al. Predicting and treating coagulopathies after cardiopulmonary bypass in children. Anesth Analg 1997; 85: 1196-1202.
120. Nuttall GA, Oliver WC, Santrach PJ, et al. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology 2001; 94: 773-781. Discussion 775A-776A.
121. Shore-Lesserson L, Manspeizer HE, DePerio M, et al. Thromboelastography- guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88: 312-319.
122. Avidan MS, Alcock EL, Da Fonseca J, et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth 2004; 92: 178-186.
123. Enriquez LJ, Shore-Lesserson L,. Point-of-care coagulation testing and transfusion algorithms. Br J Anaesth 2009; 103 (Suppl 1): i14-i22.
124. Moganasundram S, Hunt BJ, Sykes K, et al. The relationship among thromboelastography, hemostatic variables, and bleeding after cardiopulmonary bypass surgery in children. Anesth Analg 2010; 110: 995-1002.
125. Patanwala AE,. Factor VIIa (recombinant) for acute traumatic hemorrhage. Am J Health Syst Pharm 2008; 65: 1616-1623.
126. Despotis G, Avidan M, Lublin DM,. Off-label use of recombinant factor VIIA concentrates after cardiac surgery. Ann Thorac Surg 2005; 80: 3-5.
127. Warren O, Mandal K, Hadjianastassiou V, et al. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg 2007; 83: 707-714.
128. Agarwal HS, Bennett JE, Churchwell KB, et al. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg 2007; 84: 161-168.
129. Egan JR, Lammi A, Schell DN, et al. Recombinant activated factor VII in paediatric cardiac surgery. Intensive Care Med 2004; 30: 682-685.
130. Pychynska-Pokorska M, Moll JJ, Krajewski W, et al. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr Crit Care Med 2004; 5: 246-250.
131. Tobias JD, Berkenbosch JW, Russo P,. Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Pediatr Crit Care Med 2003; 4: 49-51.
132. Leibovitch L, Kenet G, Mazor K, et al. Recombinant activated factor VII for life-threatening pulmonary hemorrhage after pediatric cardiac surgery. Pediatr Crit Care Med 2003; 4: 444-446.
133. Niles SD, Burkhart HM, Duffey DA, et al. Use of recombinant factor VIIa (NovoSeven) in pediatric cardiac surgery. J Extra Corpor Technol 2008; 40: 241-248.
134. Razon Y, Erez E, Vidne B, et al. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease. Paediatr Anaesth 2005; 15: 235-240.
135. Veldman A, Neuhaeuser C, Akintuerk H, et al. rFVIIa in the treatment of persistent hemorrhage in pediatric patients on ECMO following surgery for congenital heart disease. Paediatr Anaesth 2007; 17: 1176-1181.
136. Wittenstein B, Ng C, Ravn H, et al. Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatr Crit Care Med 2005; 6: 473-476.
137. Guzzetta NA, Huch S, Fernandez JD, et al. Use of recombinant factor VIIa for uncontrolled bleeding in neonates after cardiopulmonary bypass. Paediatr Anaesth 2009; 19: 364-370.
138. Karsies TJ, Nicol KK, Galantowicz ME, et al. Thrombotic risk of recombinant factor seven in pediatric cardiac surgery: a single institution experience. Ann Thorac Surg 2010; 89: 570-576.
139. Ekert H, Brizard C, Eyers R, et al. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagul Fibrinolysis 2006; 17: 389-395.
140. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 293-298.